Microbiome Changes during Tuberculosis and Antituberculous Therapy

Clin Microbiol Rev. 2016 Oct;29(4):915-26. doi: 10.1128/CMR.00096-15. Epub 2016 Sep 8.

Abstract

The critical role of commensal microbiota in the human body has been increasingly recognized, and our understanding of its implications in human health and disease has expanded rapidly. The lower respiratory tract contains diverse communities of microbes known as lung microbiota, which are present in healthy individuals and in individuals with respiratory diseases. The dysbiosis of the airway microbiota in pulmonary tuberculosis (TB) may play a role in the pathophysiological processes associated with TB disease. Recent studies of the lung microbiome have pointed out changes in lung microbial communities associated with TB and other lung diseases and have also begun to elucidate the profound effects that antituberculous drug therapy can have on the human lung microbiome composition. In this review, the potential role of the human microbiome in TB pathogenesis and the changes in the human microbiome with Mycobacterium tuberculosis infection and TB therapy are presented and discussed.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Antitubercular Agents / therapeutic use*
  • Dysbiosis
  • Humans
  • Microbiota / drug effects*
  • Respiratory System / microbiology*
  • Tuberculosis / drug therapy*

Substances

  • Antitubercular Agents